Short interest for PaxMedica gives investors a sense of the degree to which investors are betting on the decline of PaxMedica's stock. Short interest data is updated every two weeks.

PaxMedica Stock (NASDAQ:PXMD), Short Interest Report

PaxMedica

PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.

Earnings

News

Penny Stocks

Eurozone

Commodities

Global

Intraday Update

Markets

Trading Ideas

LGVN

MRNS

ONVO

PXMD

SNGX

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday.

The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&amp;P 500 also rose, gaining, 0.80% to 5,164.30.

Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings

Small Cap

APLD

EZGO

MOTS

NXPL

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 500 points on Friday.

The Dow traded down 1.37% to 37,934.02 while the NASDAQ fell 1.82% to 16,142.15. The S&amp;P 500 also fell, dropping, 1.61% to 5,115.54.

Nasdaq Down 300 Points; BlackRock Posts Upbeat Earnings

Movers

ADIL

AGEN

ALLR

ANET

BENF

CISS

CMAX

CPNG

DXYZ

FRGE

GATO

GCTS

HRYU

HUBC

INTZ

LOVE

LXEH

LYEL

MGRM

MNDR

MOGU

MRIN

NKLA

NRIX

RENT

RLYB

SAVA

SBFM

SERA

VERU

VIAO

Shares of  JPMorgan Chase &amp; Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings.

Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

PaxMedica Inc

Guidance

LUMN

Lumen Technologies Reiterates 2024 Financial Outlook, Adjusted EBITDA At $4.1B-$4.3B

USLM

United States Lime & Minerals Q1 2024 EPS $3.92 Up From $3.00 YoY;  Revenue $71.7M Up From $66.8M YoY

HomeStreet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HMST#NASDAQ">HMST</a>) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.08) by 400 percent.

Earnings Misses

HMST

HomeStreet Q1 2024 GAAP EPS $(0.40) Misses $(0.08) Estimate

Ponce Finl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDLB#NASDAQ">PDLB</a>) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $(0.03) by 466.67 percent.

Earnings Beats

PDLB

Ponce Finl Gr Q1 2024 GAAP EPS $0.11 Beats $(0.03) Estimate

BHAT

Blue Hat FY23 Revenue 73.68M

Gevo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) has issued a response to the recently unveiled version of the Argonne National Laboratory Greenhouse Gases, Regulated Emissions, and Energy use in Technologies (GREET) method and model for carbon accounting. This model will be utilized for lifecycle greenhouse gas emissions calculations under the Inflation Reduction Act's (IRA) Section 40B sustainable aviation fuel (SAF) tax credits.
"Today's guidance reinforces the importance of climate-smart agriculture and other decarbonization methods like carbon capture and storage (CCS) – core tenets of Gevo's business model for sustainable aviation fuel and other products," said Dr. Patrick R. Gruber, CEO of Gevo. "Our cutting-edge programs source sustainable feedstocks produced using a variety of climate-smart agricultural practices, and our Verity carbon accounting tool allows farmers to incorporate and track emissions reduction practices tailored to their individual fields. We look forward to sharing key insights from anonymized data to inform the Administration's upcoming 45Z SAF tax credit guidance – and we will continue to advocate for science-based policies that support CCS and provide new markets for farmers focused on carbon abatement from agricultural activities."
For nearly two decades, Gevo has led the research and development of new fuels and products that support the decarbonization of transportation and help industries reach their net-zero goals, including agriculture. Gevo has advocated for use of GREET as the science-based carbon accounting tool to determine the lifecycle carbon intensity of SAF and ensure important emissions reductions throughout the SAF supply chain – including from climate-smart agriculture practices and carbon capture and storage – are accounted for and credited, while maintaining GREET's data-driven integrity.
Gevo's wholly owned subsidiary, Verity, uses distributed ledger technology to facilitate accurate accounting of emission reduction efforts from on-farm practices, including on a field-level basis. This auditable technology allows farmers to track and report the carbon reductions they achieve, including through climate-smart agriculture and other practices. Gevo partners with farmers using Verity to work collaboratively to identify emissions reductions opportunities that are tailored to field-level needs.
Dr. Gruber concluded, "Today, the Administration's actions recognize the power of agriculture and lay the groundwork for implementation of future SAF tax credits. A science-based approach to the Section 45Z credit will ensure that biofuel producers, supported by American farmers, play a vital role in scaling&nbsp;the hard-to-decarbonize aviation industry."
SAF with greenhouse gas emissions that are at least 50% lower than conventional aviation fuel will qualify for tax credits created by the IRA. Gevo has long believed that the GREET lifecycle analysis method and model enables the most current and precise measurement of SAF carbon intensity, accurately counting carbon reduction benefits of agricultural feedstocks, including at the field level. In&nbsp;<a href="https://www.globenewswire.com/Tracker?data=lPZREAgR5EKSO8Pv4gc1CFlzfTehzWBk8zYnzbfOMealzWGw1iF3evCiqVLitzu1hKYyRuYkJiZKtbQRf2m2w7-rFwmIRuvTlw4cHelhsY7Ry_IulilK2KuWEOR5KoZZONgkQFWqM93DUQw3Zf3q2ahE0-RrvtmCZ3yOPZhH7BiHjrtlLBkOXN4nqLJ6iC6pz9G3zIAmxxJuSLw1H76BOA==">December 2023,</a>&nbsp;Gevo applauded the Administration's announcement to include the Argonne GREET model as a "similar methodology" under the IRA Section 40B tax credit; and we believe today's Section 40B model rightfully puts a premium on driving down carbon abatement throughout the value chain.
With completion of the Argonne GREET 40B SAF tax credit model, Gevo expects the Administration to expand on climate smart ag practices and flexibility when implementing the IRA Section 45Z SAF tax credit. Clear and timely rules for the 45Z Clean Fuel Production tax credit in effect from 2025 through 2027 will be critical to meeting carbon abatement goals and helping farmers plan for successful growing seasons, without stranding SAF investments.

GEVO

Gevo's Announces Co's Sustainable Aviation Fuel Well-Positioned In Light Of New Guidance From Treasury Department

Biotech

General

NBIX

Neurocrine Biosciences Announces FDA Approval Of INGREZZA SPRINKLE Capsules

ROKU

Roku Debuts New Video Experiences, Ad Solutions, And New Content Partnerships

Dividends

PCAR

PACCAR Increases Quarterly Dividend From $0.27 To $0.30

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.iconplc.com%2F&amp;esheet=53968413&amp;newsitemid=20240430675153&amp;lan=en-US&amp;anchor=ICON+plc&amp;index=1&amp;md5=0c82fd737039557352788a913a0e252e">ICON plc</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) ("ICON"), a world-leading healthcare intelligence and clinical research organization, today announced the pricing of a USD 2 billion SEC-registered bond offering, consisting of $750,000,000 5.809% Senior Secured Notes due 2027, $750,000,000 5.849% Senior Secured Notes due 2029 and $500,000,000 6.000% Senior Secured Notes due 2034 (collectively, the "Notes").
The Notes will be issued by ICON's wholly-owned subsidiary, ICON Investments Six Designated Activity Company (the "Issuer"), and will be guaranteed on a senior secured basis by ICON and its existing and future wholly owned subsidiaries organized in the United States, Ireland and the Grand Duchy of Luxembourg ("Luxembourg") (the "Subsidiary Guarantors" and, collectively with ICON, the "Guarantors"), in each case that guarantee the obligations under our senior secured U.S. dollar denominated term loan facility and senior secured revolving credit facility (together, the "Senior Secured Credit Facilities") and the 2.875% senior secured notes due 2026 issued by PRA Health Sciences, Inc., a wholly owned subsidiary of ICON (the "Existing Notes"). The Notes will be senior secured obligations of the Issuer and the Guarantors and the Notes will rank equally in right of payment to all of the Issuer's and Guarantors' existing and future senior debt (including the Senior Secured Credit Facilities and the Existing Notes) and senior in right of payment to all of the Issuer's and Guarantors' existing and future subordinated debt.
The offering is expected to close on May 8, 2024, subject to the satisfaction of customary closing conditions.

Offerings

ICLR

ICON Announces Pricing Of $2B Notes

Boston Properties Sees FY24 FFO $6.98-$7.10

Boston Properties Sees Q2 2024 FFO $1.70-$1.72 Vs $1.78 Est.

Kyle&nbsp;Loudermilk has submitted a letter of resignation to the Board of Directors and will remain with the company through&nbsp;May 31, 2024&nbsp;to assist in transition.

Management

GSE Solutions Names Ravi Khanna As President And CEO, Effective Immediately

Boston Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>) reported quarterly earnings of $1.73 per share which met the analyst consensus estimate. The company reported quarterly sales of $839.439 million which beat the analyst consensus estimate of $808.618 million by 3.81 percent. This is a 4.51 percent increase over sales of $803.200 million the same period last year.

Boston Props Q1 2024 FFO $1.73, Inline, Sales $839.439M Beat $808.618M Estimate

WBUY

Webuy Announces Pricing Up To 10M Share Offering At $0.29/Share

For the&nbsp;second quarter&nbsp;of 2024, Ryerson expects customer shipments to increase&nbsp;1%&nbsp;to&nbsp;3%, quarter-over-quarter. The Company&nbsp;expects adjusted EBITDA, excluding LIFO in the range of&nbsp;$47 million&nbsp;to&nbsp;$53 million.

Ryerson Anticipates Q2 Net Sales Of $1.25B-$1.29B (Est $1.222B), EPS Of $0.15-$0.25

Blue Ridge Bankshares (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BRBS#AMEX">BRBS</a>) reported quarterly losses of $(0.15) per share. This is a 171.43 percent decrease over earnings of $0.21 per share from the same period last year.

BRBS

Blue Ridge Bankshares Q1 EPS $(0.15) Down From $0.21 YoY

MACK

Merrimack Pharmaceuticals To Voluntary Delist Common Stock On NASDAQ

<ul>
<li>an increase in FirstSun's total equity capital raised in connection with the merger of an additional $45 million to $60 million, resulting in an increase from an aggregate capital raise of $175 million to up to $235 million (as further discussed below);</li>
<li>a revised exchange ratio pursuant to which HomeStreet shareholders will receive 0.3867 shares (revised from 0.4345 shares under the original merger agreement) of FirstSun common stock for each share of HomeStreet common stock, which represents a value of $13.53 per share (based on the closing price per share of FirstSun shares on April 29, 2024);</li>
<li>a reduced termination fee payable by HomeStreet in certain circumstances if HomeStreet receives a competing acquisition proposal within 30 days after the effective date of the Amendment to $2,600,000, plus reimbursement of FirstSun's transaction fees and expenses;</li>
<li>that the combined company's ongoing banking operations will operate under a Texas state charter with FirstSun's subsidiary bank, Sunflower Bank, converting from a national bank to a Texas state chartered bank and that Sunflower Bank will also seek membership in the Federal Reserve System;</li>
<li>FirstSun's issuance of $48.5 million of subordinated debt concurrently with the closing, the proceeds of which will be contributed to Sunflower Bank to further support Sunflower Bank's capital; and</li>
<li>HomeStreet's disposition or sale of approximately $300 million (based on principal balance) of certain of its Commercial Real Estate loans, which disposition or loan sales will be consummated upon, or as soon as reasonably practicable, after the closing of the merger</li>
</ul>

FSUN

FirstSun Capital Bancorp And HomeStreet Amend Merger Agreement; Increase In Firstsun's Total Equity Capital Raised In Connection With Merger Of Additional $45M-60M; Revised Ratio Which HomeStreet Shareholders Receive 0.3867 Shares

Enstar Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESGR#NASDAQ">ESGR</a>) has announced today that one of its wholly-owned subsidiaries has reached an agreement for a loss portfolio transfer with a subsidiary of SiriusPoint Ltd. ("SiriusPoint") to reinsure a $400 million portfolio of Workers' Compensation business covering underwriting years 2018 to 2023. &nbsp;
Under the reinsurance agreement, which will be entered into at closing, SiriusPoint will cede net reserves of approximately $400 million, and Enstar's subsidiary will provide approximately $200 million of cover in excess of the ceded reserves, with claims management transferring to Enstar.
The transaction, in which Guy Carpenter acted as the broker, will close upon receipt of regulatory approvals and satisfaction of other customary closing conditions.
Dominic Silvester, Enstar's Chief Executive Officer, said: "Our partnership with SiriusPoint aligns with our expertise and track record of outperformance in US Workers' Compensation and demonstrates our capabilities to structure and execute sophisticated risk solutions. For SiriusPoint, this bespoke transaction will help to support its long-term strategic, economic and operational goals."

ESGR

Enstar Agrees $400M Loss Portfolio Transfer With SiriusPoint

XPEV, MTA and PXMD are among pre market gainers

PaxMedica, Inc. (PXMD) has received a new Buy rating, initiated by H.C. Wainwright analyst, Boobalan Pachaiyappan. Boobalan Pachaiyappan has given ...

Buy Rating on PaxMedica: Strategic Value of Suramin and PRV in Neurological Disorder Treatments

PaxMedica, Inc. (PXMD) has shared an update. PaxMedica, Inc. has released an updated corporate slide presentation on its website for use in discuss...

PaxMedica Releases Updated Investor Presentation Online

PaxMedica shares soar 125% post-market on drug update

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Friday is here and we&rsquo;re starting the final day of trading this week with a breakdown of the biggest pre-market stock movers this morning!



Moving stocks this morning are earnings reports, stakeholder updates, drug development news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>PaxMedica (NASDAQ:<a href="https://investorplace.com/stock-quotes/pxmd-stock-quote/">PXMD</a>) stock is rocketing close to 82% after hitting a <a href="https://www.nasdaq.com/press-release/paxmedica-achieves-key-milestone-in-the-development-of-pax-101-and-provides-update-on">key milestone in drug development</a>.</li>



<li>Allarity Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) shares are soaring more than 61% alongside heavy pre-market trading.</li>



<li>Zapata Computing (NASDAQ:<a href="https://investorplace.com/stock-quotes/zpta-stock-quote/">ZPTA</a>) stock is surging over 36% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318230226&amp;type=PDF&amp;symbol=ZPTA&amp;cdn=e948601bd73c48c35f25d9d7dd224e92&amp;companyName=Zapata+Computing+Holdings+Inc.&amp;formType=SC+13G%2FA&amp;formDescription=%5BAmend%5D+Statement+of+acquisition+of+beneficial+ownership+by+individuals&amp;dateFiled=2024-04-11">following a stakeholder update</a>.</li>



<li>NextPlat (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxpl-stock-quote/">NXPL</a>) shares are rising 32% alongside a <a href="https://www.nasdaq.com/press-release/nextplat-reports-consolidated-year-end-2023-results-with-increased-revenues-of-%2437.8">positive 2023 earnings report</a>.</li>



<li>AMTD Digital (NYSE:<a href="https://investorplace.com/stock-quotes/hkd-stock-quote/">HKD</a>) stock is increasing more than 25% with strong early morning trading.</li>



<li>Beneficient (NASDAQ:<a href="https://investorplace.com/stock-quotes/benf-stock-quote/">BENF</a>) shares are gaining over 25% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318230412&amp;type=PDF&amp;symbol=BENF&amp;cdn=eb254668ceab70d3f25ad97304b464e9&amp;companyName=Beneficient&amp;formType=SC+13D%2FA&amp;formDescription=%5BAmend%5D+General+statement+of+acquisition+of+beneficial+ownership&amp;dateFiled=2024-04-11">a stakeholder update</a>.</li>



<li>NRX Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/nrxp-stock-quote/">NRXP</a>) stock is heading more than 18% higher <a href="https://www.nasdaq.com/press-release/nrxs-nasdaq%3a-nrxp-nmda-modification-therapy-and-its-multiple-applications-from-mental">on therapy news</a>.</li>



<li>Lyell Immunopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/lyel-stock-quote/">LYEL</a>) shares are jumping over 15% this morning.</li>



<li>Soligenix (NASDAQ:<a href="https://investorplace.com/stock-quotes/sngx-stock-quote/">SNGX</a>) stock is climbing more than 14% on <a href="https://www.nasdaq.com/press-release/fda-grants-soligenix-orphan-drug-designation-for-the-prevention-and-post-exposure">positive drug news</a>.</li>



<li>OncoCyte (NASDAQ:<a href="https://investorplace.com/stock-quotes/ocx-stock-quote/">OCX</a>) shares are up over 14% with its <a href="https://ng.investing.com/news/stock-market-news/oncocyte-reports-full-year-2023-financial-results-93CH-1298708">Q4 earnings report</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Motus GI (NASDAQ:<a href="https://investorplace.com/stock-quotes/mots-stock-quote/">MOTS</a>) stock is plummeting more than 35% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318230488&amp;type=PDF&amp;symbol=MOTS&amp;cdn=84b00af3974179838345280e52876622&amp;companyName=Motus+GI+Holdings+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-11">on a delisting warning</a>.</li>



<li>Spectaire (NASDAQ:<a href="https://investorplace.com/stock-quotes/spec-stock-quote/">SPEC</a>) shares are diving 17% despite a lack of news today.</li>



<li>Rent the Runway (NASDAQ:<a href="https://investorplace.com/stock-quotes/rent-stock-quote/">RENT</a>) stock is retreating over 15% <a href="https://investorplace.com/2024/04/why-is-rent-the-runway-rent-stock-up-30-today/">after rallying yesterday</a>.</li>



<li>Monogram Orthopaedics (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgrm-stock-quote/">MGRM</a>) shares are tumbling more than 13% as it <a href="https://www.nasdaq.com/press-release/monogram-accepted-to-nvidia-inception-program-2024-04-11">also jumped higher yesterday</a>.</li>



<li>Rallybio (NASDAQ:<a href="https://investorplace.com/stock-quotes/rlyb-stock-quote/">RLYB</a>) stock is pulling back over 11% after a <a href="https://investorplace.com/2024/04/why-is-rallybio-rlyb-stock-up-93-today/">major rally on Thursday</a>.</li>



<li>Applied Digital (NASDAQ:<a href="https://investorplace.com/stock-quotes/apld-stock-quote/">APLD</a>) shares are falling more than 11% with its <a href="https://finance.yahoo.com/news/applied-digital-reports-fiscal-third-200500599.html">fiscal Q3 2024 earnings report</a>.</li>



<li>Kazia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) stock is taking an over 10% beating without any clear news this morning.</li>



<li>MOGU (NYSE:<a href="https://investorplace.com/stock-quotes/mogu-stock-quote/">MOGU</a>) shares are decreasing more than 10% with no obvious news to report.</li>



<li>Marin Software (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrin-stock-quote/">MRIN</a>) stock is dropping over 10% <a href="https://investorplace.com/2024/04/why-is-marin-software-mrin-stock-up-62-today/">after rallying recently</a>.</li>



<li>GCT Semiconductor (NYSE:<a href="https://investorplace.com/stock-quotes/gcts-stock-quote/">GCTS</a>) shares close out our pre-market stock movers down more than 10%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-april-12th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
PaxMedica&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/pxmd-stock-quote/">PXMD</a>) stock is rocketing higher on Friday after the clinical-stage biopharmaceutical company <a href="https://www.nasdaq.com/press-release/paxmedica-achieves-key-milestone-in-the-development-of-pax-101-and-provides-update-on">reached a key milestone</a> in drug development.



The big news here is the company securing three pivotal registration/validation batches of PAX-101. The company says that this is a key milestone in its plans for a New Drug Application (NDA) set for Q4 2024.



Investors are celebrating this news as it puts PAX-101 one step closer to approval from the Food and Drug Administration&nbsp;(FDA). If approved, it would be the first first and only form of suramin for the treatment of Stage 1 Human African Trypanosomiasis.



<h2>What&rsquo;s Next for PXMD Stock?</h2>



Howard Weisman, chairman and CEO of&nbsp;PaxMedica, said the following about the company&rsquo;s next plan for PAX-101.




&ldquo;The long-term vision for PaxMedica is to further clinical investigation of PAX-101 as a treatment for individuals who struggle with Autism Spectrum Disorder. With this important manufacturing milestone completed, we have removed a major impediment to testing PAX-101 as a treatment for the core symptoms of Autism Spectrum Disorder.&rdquo;




All of this news brings with it heavy trading of PXMD stock this morning. That has more than 5 million shares changing hands as of this writing. That&rsquo;s quite the leap over its daily average trading volume of about 240,000 shares.



PXMD stock is up 92.7% as of Friday morning.



There are more stock market stories traders need to know about on Friday!



Luckily, we have all of the hottest stock market news ready to go today! That starts with our biggest pre-market stock movers this morning while also catching investors up on yesterday&rsquo;s news. You can dive into all of that at the links below!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-april-12th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Friday</a></li>



<li><a href="https://investorplace.com/2024/04/5-investors-betting-big-on-rent-the-runway-rent-stock/">5 Investors Betting Big on Rent the Runway (RENT) Stock</a></li>



<li><a href="https://investorplace.com/2024/04/cantor-fitzgerald-just-raised-its-rating-on-soundhound-ai-soun-stock/">Cantor Fitzgerald Just Raised Its Rating on SoundHound AI (SOUN) Stock</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/why-is-paxmedica-pxmd-stock-up-93-today/">Why Is PaxMedica (PXMD) Stock Up 93% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is PaxMedica (PXMD) Stock Up 93% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Allarity Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) stock is heading higher on Friday alongside heavy pre-market trading.



Investors will note that this movement comes after the company <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318229974&amp;type=PDF&amp;symbol=ALLR&amp;cdn=994a98b62336e93eb05e904c271966d1&amp;companyName=Allarity+Therapeutics+Inc.&amp;formType=424B5&amp;formDescription=Prospectus+%5BRule+424%28b%29%285%29%5D&amp;dateFiled=2024-04-11">announced a prospectus supplement</a>. This alters the maximum aggregate offering price of shares sold through prospectus from $1,350,000 to $2,350,000.



Allarity Therapeutics notes that it currently has 828,580 shares outstanding with a value of $7,092,593. The amendment mentions that the company has sold $1,348,908 worth of its shares and is eligible to sell $1,015,290 more.



<h2>ALLR Stock Movement Today</h2>



The heavy pre-market trading has more than 2.8 million shares of the clinical-stage biopharmaceutical company&rsquo;s stock changing hands. That&rsquo;s well above its daily average trading volume of about 59,000 shares.



Investors will also note that ALLR stock is up 41.3% as of Friday morning. Even so, the shares closed out Thursday down 78.9% since the start of the year.



Another thing to note is that ALLR is a penny stock. This comes from its low daily average trading volume, prior closing price of $2.30 per share and market capitalization of only $1.0821.082. All of these make it a risky investment.



There are even more of the most recent stock market stories traders will want to read about today below!



We are offering all of the hottest stock market news that investors need to know about on Friday! Among that is what has shares of PaxMedica&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/pxmd-stock-quote/">PXMD</a>) stock rising, the biggest pre-market stock movers this morning and more. All of this info is ready to go at the following links!



<h2>More Stock Market News for Friday</h2>



<ul><li><a href="https://investorplace.com/2024/04/why-is-paxmedica-pxmd-stock-up-93-today/">Why Is PaxMedica (PXMD) Stock Up 93% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-april-12th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Friday</a></li>



<li><a href="https://investorplace.com/2024/04/5-investors-betting-big-on-rent-the-runway-rent-stock/">5 Investors Betting Big on Rent the Runway (RENT) Stock</a></li>
</ul>On <a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a> and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/why-is-allarity-therapeutics-allr-stock-up-41-today/">Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Motus GI&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mots-stock-quote/">MOTS</a>) stock is falling on Friday following a warning that the medical technology company is in danger of being delisted.



Motus GI <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318230488&amp;type=PDF&amp;symbol=MOTS&amp;cdn=84b00af3974179838345280e52876622&amp;companyName=Motus+GI+Holdings+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-11">got a delisting notice</a> from the Listing Qualifications Staff of the Nasdaq Exchange on April 5. In that notice, the company was warned about a potential delisting due to its low shares price.



Shares of MOTS stock have been trading for less than $1 each for over 30 business days. That has the company not complying with the minimum bid to remain listed on the exchange.



On that same note, Motus GI has enacted reverse stock splits with a ratio of 250 shares or more to one over the last year. That makes it ineligible for a compliance period to regain the $1 minimum bid.



<h2>What This Means for MOTS Stock</h2>



Motus GI has until today to request a hearing with the Nasdaq Exchange to try and avoid delisting. However, the company doesn&rsquo;t believe it can regain compliance and is choosing not to seek a hearing.



As a result, shares of MOTS stock will stop trading on the Nasdaq Exchange when markets open on Tuesday. This will result in its shares switching over to the OTC Pink Market of the OTCMarkets. It intends to apply for listing on the OTCQB.



Finally, Motus GI says it is exploring a range of strategic options. Its doing so to maximize shareholder value while speeding up the commercialization of its Pure-Vu System.



MOTS stock is down 37.1% as of Friday morning.



There are more stock market stories traders are going to want to read about!



Fortunately, we have a full list of stock market happenings worth reading on Friday! A few examples include what&rsquo;s sending shares of Allarity Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) and PaxMedica&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/pxmd-stock-quote/">PXMD</a>) stock higher, as well as the biggest pre-market stock movers this morning. All of that info is available below!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/04/why-is-allarity-therapeutics-allr-stock-up-41-today/">Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-paxmedica-pxmd-stock-up-93-today/">Why Is PaxMedica (PXMD) Stock Up 93% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-april-12th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Friday</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/why-is-motus-gi-mots-stock-down-37-today/">Why Is Motus GI (MOTS) Stock Down 37% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Motus GI (MOTS) Stock Down 37% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Applied Digital&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/apld-stock-quote/">APLD</a>) stock is falling on Friday following the release of the data center company&rsquo;s earnings report for its fiscal third quarter of 2024.



The bad news for APLD stockholders starts with the company&rsquo;s <a href="https://finance.yahoo.com/news/applied-digital-reports-fiscal-third-200500599.html">adjusted earnings per share of -24 cents</a>. That&rsquo;s much worse than the -7 cents per share that Wall Street was expecting. It&rsquo;s also a significant setback compared to the -1 cent per share from the same period of the year prior.



Also not helping matters is Applied Digital&rsquo;s revenue of $43.35 million in fiscal Q3 2024. That&rsquo;s another miss next to analysts&rsquo; revenue estimate of $51.92 million. This is despite it increasing 208% year-over-year from $14.09 million.



Wes Cummins, chairman and CEO of Applied Digital, said this in the earnings report.




&ldquo;During the quarter, Applied Digital encountered several challenges that impacted our financial performance due to facility power outages in our datacenter hosting business. Despite these short-term setbacks, we made significant progress with our key growth initiatives in the development of our Cloud Services business and the establishment of our special purpose built 100 MW HPC datacenter in Ellendale.&rdquo;




<h2>APLD Stock Movement Today</h2>



Investors aren&rsquo;t happy about these latest earnings results from Applied Digital. That has shares of APLD stock falling 5.5% as of Friday morning. That builds on a 55.9% decrease year-to-date as of Thursday&rsquo;s close.



With today&rsquo;s drop in price comes roughly 216,000 shares of APLD stock changing hands. That&rsquo;s well below its daily average trading volume of about 3.5 million shares.



Investors will find even more of the most recent stock market news below!



We have all of the hottest stock market stories worth reading about on Friday! That includes what&rsquo;s going on with shares of Motus GI&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mots-stock-quote/">MOTS</a>) stock, Allarity Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) stock and PaxMedica&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/pxmd-stock-quote/">PXMD</a>) stock this morning. All of that info is available at the following links!



<h2>More Stock Market News for Friday</h2>



<ul><li><a href="https://investorplace.com/2024/04/why-is-motus-gi-mots-stock-down-37-today/">Why Is Motus GI (MOTS) Stock Down 37% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-allarity-therapeutics-allr-stock-up-41-today/">Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-paxmedica-pxmd-stock-up-93-today/">Why Is PaxMedica (PXMD) Stock Up 93% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/why-is-applied-digital-apld-stock-down-6-today/">Why Is Applied Digital (APLD) Stock Down 6% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Applied Digital (APLD) Stock Down 6% Today?

DCFC, HUSA and INDO among mid-day movers

BROG

CAPT

DCFC

FEAM

HGAS

HNRA

HUSA

INDO

KUKE

KZIA

LICY

MDIA

NRXP

SLNH

SPEC

TPET

XPEV

ZPTA

Press Releases

PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business Update

Health Care

PaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data

PaxMedica Announces Pricing of $7.0 Million Public Offering

PaxMedica Announces Closing of $7.0 Million Public Offering

PaxMedica Releases Fireside Chat Video with CEO Howard Weisman

PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments

PaxMedica Achieves Key Milestone in the Development of PAX-101  And Provides Update on Potential NDA Submission

PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness

PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101

PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast

-

-

-

-

-

-

-

-

-

-

-

-

-

-

PaxMedica Stock (NASDAQ:PXMD), Short Interest Report

People Also Watch